Advertisement
American Journal of Kidney Diseases

Dialysis Modality and Incident Atrial Fibrillation in Older Patients With ESRD

Published:November 15, 2018DOI:https://doi.org/10.1053/j.ajkd.2018.09.011

      Rationale & Objective

      Atrial fibrillation (AF) is common in patients with kidney failure treated by maintenance dialysis. Whether the incidence of AF differs between patients receiving hemodialysis and peritoneal dialysis is uncertain.

      Study Design

      Retrospective cohort study.

      Setting & Participants

      Using the US Renal Data System, we identified older patients (≥67 years) with Medicare Parts A and B who initiated dialysis therapy (1996-2011) without a diagnosis of AF during the prior 2 years.

      Exposure

      Dialysis modality at incident end-stage renal disease (ESRD) and maintained for at least 90 days.

      Outcome

      Patients were followed up for 36 months or less for a new diagnosis of AF.

      Analytical Approach

      Time-to-event analysis using multivariable Cox proportional hazards regression to estimate cause-specific HRs while censoring at modality switch, kidney transplantation, or death.

      Results

      Overall, 271,722 older patients were eligible; 17,487 (6.9%) were treated with peritoneal dialysis, and 254,235 (93.1%), with hemodialysis, at the onset of ESRD. During 406,225 person-years of follow-up, 69,705 patients had AF newly diagnosed. Because the proportionality assumption was violated, we introduced an interaction term between time (first 90 days vs thereafter) and modality. The AF incidence during the first 90 days was 187/1,000 person-years on peritoneal dialysis therapy and 372/1,000 person-years on hemodialysis therapy. Patients on peritoneal dialysis therapy had an adjusted 39% (95% CI, 34%-43%) lower incidence of AF than those on hemodialysis therapy. From day 91 onward, AF incidence was ∼140/1,000 person-years with no major difference between modalities.

      Limitations

      Residual confounding from unobserved differences between exposure groups; ascertainment of AF from billing claims; study of first modality may not generalize to patients switching modalities; uncertain generalizability to younger patients.

      Conclusions

      Although patients initiating dialysis therapy using peritoneal dialysis had a lower AF incidence during the first 90 days of ESRD, there was no major difference in AF incidence thereafter. The value of interventions to reduce the early excess AF risk in patients receiving hemodialysis may warrant further study.

      Index Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Winkelmayer W.C.
        • Patrick A.R.
        • Liu J.
        • Brookhart M.A.
        • Setoguchi S.
        The increasing prevalence of atrial fibrillation among hemodialysis patients.
        J Am Soc Nephrol. 2011; 22: 349-357
        • Goldstein B.A.
        • Arce C.M.
        • Hlatky M.A.
        • Turakhia M.
        • Setoguchi S.
        • Winkelmayer W.C.
        Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States.
        Circulation. 2012; 126: 2293-2301
        • Staerk L.
        • Sherer J.A.
        • Ko D.
        • Benjamin E.J.
        • Helm R.H.
        Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes.
        Circ Res. 2017; 120: 1501-1517
        • Kim M.H.
        • Johnston S.S.
        • Chu B.C.
        • Dalal M.R.
        • Schulman K.L.
        Estimation of total incremental health care costs in patients with atrial fibrillation in the United States.
        Circ Cardiovasc Qual Outcomes. 2011; 4: 313-320
        • Rubin A.L.
        • Lubash G.D.
        • Cohen B.D.
        • Brailovsky D.
        • Braveman W.S.
        • Luckey E.H.
        Electrocardiographic changes during hemodialysis with the artificial kidney.
        Circulation. 1958; 18: 227-234
        • Saran R.
        • Robinson B.
        • Abbott K.C.
        • et al.
        US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States.
        Am J Kidney Dis. 2017; 69: A7-A8
        • Lau B.
        • Cole S.R.
        • Gange S.J.
        Competing risk regression models for epidemiologic data.
        Am J Epidemiol. 2009; 170: 244-256
        • Montez-Rath M.E.
        • Winkelmayer W.C.
        • Desai M.
        Addressing missing data in clinical studies of kidney diseases.
        Clin J Am Soc Nephrol. 2014; 9: 1328-1335
        • Konigsbrugge O.
        • Posch F.
        • Antlanger M.
        • et al.
        Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross-sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).
        PLoS One. 2017; 12: e0169400
        • Roy-Chaudhury P.
        • Tumlin J.A.
        • Koplan B.A.
        • et al.
        Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.
        Kidney Int. 2018; 93: 941-951
        • Zimmerman D.
        • Sood M.M.
        • Rigatto C.
        • Holden R.M.
        • Hiremath S.
        • Clase C.M.
        Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis.
        Nephrol Dial Transplant. 2012; 27: 3816-3822
        • Airy M.
        • Chang T.I.
        • Ding V.Y.
        • et al.
        Risk profiles for acute health events after incident atrial fibrillation in patients with end-stage renal disease on hemodialysis.
        Nephrol Dial Transplant. 2018; 33: 1590-1597
        • Shah M.
        • Avgil Tsadok M.
        • Jackevicius C.A.
        • et al.
        Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.
        Circulation. 2014; 129: 1196-1203
        • Shen J.I.
        • Montez-Rath M.E.
        • Lenihan C.R.
        • Turakhia M.P.
        • Chang T.I.
        • Winkelmayer W.C.
        Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation.
        Am J Kidney Dis. 2015; 66: 677-688
        • Shih C.J.
        • Ou S.M.
        • Chao P.W.
        • et al.
        Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort.
        Circulation. 2016; 133: 265-272
        • Chan K.E.
        • Edelman E.R.
        • Wenger J.B.
        • Thadhani R.I.
        • Maddux F.W.
        Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis.
        Circulation. 2015; 131: 972-979
        • Wetmore J.B.
        • Mahnken J.D.
        • Rigler S.K.
        • et al.
        The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients.
        Kidney Int. 2012; 81: 469-476
        • Vazquez E.
        • Sanchez-Perales C.
        • Garcia-Garcia F.
        • et al.
        Atrial fibrillation in incident dialysis patients.
        Kidney Int. 2009; 76: 324-330
        • Shen C.H.
        • Zheng C.M.
        • Kiu K.T.
        • et al.
        Increased risk of atrial fibrillation in end-stage renal disease patients on dialysis: a nationwide, population-based study in Taiwan.
        Medicine (Baltimore). 2016; 95: e3933
        • Weinhandl E.D.
        • Foley R.N.
        • Gilbertson D.T.
        • Arneson T.J.
        • Snyder J.J.
        • Collins A.J.
        Propensity-matched mortality comparison of incident hemodialysis and peritoneal dialysis patients.
        J Am Soc Nephrol. 2010; 21: 499-506
        • Perl J.
        • Wald R.
        • McFarlane P.
        • et al.
        Hemodialysis vascular access modifies the association between dialysis modality and survival.
        J Am Soc Nephrol. 2011; 22: 1113-1121
        • Chan K.E.
        • Maddux F.W.
        • Tolkoff-Rubin N.
        • Karumanchi S.A.
        • Thadhani R.
        • Hakim R.M.
        Early outcomes among those initiating chronic dialysis in the United States.
        Clin J Am Soc Nephrol. 2011; 6: 2642-2649
        • Moride Y.
        • Abenhaim L.
        Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research.
        J Clin Epidemiol. 1994; 47: 731-737
        • Hanson J.A.
        • Hulbert-Shearon T.E.
        • Ojo A.O.
        • et al.
        Prescription of twice-weekly hemodialysis in the USA.
        Am J Nephrol. 1999; 19: 625-633
        • Kalantar-Zadeh K.
        • Unruh M.
        • Zager P.G.
        • et al.
        Twice-weekly and incremental hemodialysis treatment for initiation of kidney replacement therapy.
        Am J Kidney Dis. 2014; 64: 181-186
        • Obi Y.
        • Streja E.
        • Rhee C.M.
        • et al.
        Incremental hemodialysis, residual kidney function, and mortality risk in incident dialysis patients: a cohort study.
        Am J Kidney Dis. 2016; 68: 256-265
        • Buiten M.S.
        • de Bie M.K.
        • Rotmans J.I.
        • et al.
        The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients.
        Heart. 2014; 100: 685-690
        • Korantzopoulos P.
        • Kolettis T.M.
        • Galaris D.
        • Goudevenos J.A.
        The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation.
        Int J Cardiol. 2007; 115: 135-143
        • Marron B.
        • Remon C.
        • Perez-Fontan M.
        • Quiros P.
        • Ortiz A.
        Benefits of preserving residual renal function in peritoneal dialysis.
        Kidney Int Suppl. 2008; 108: S42-S51
        • Alonso A.
        • Agarwal S.K.
        • Soliman E.Z.
        • et al.
        Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study.
        Am Heart J. 2009; 158: 111-117